Deferred Compensation and Other Non-current Liabilities	3 Months Ended
	Mar. 31, 2025
Payables and Accruals [Abstract]
Deferred Compensation and Other Non-current Liabilities	Deferred Compensation and Other Noncurrent LiabilitiesIn March 2012, the Company entered into employee retention arrangements with certain former executive officers, whereby the Company is required to make payments to such former officers based on net revenues of voclosporin for a certain period of time. As of March 31, 2025 and December 31, 2024, the Company recorded other deferred compensation and other noncurrent liabilities of $11.4 million and $9.4 million, respectively.